# A Study of Baricitinib (LY3009104) in Participants With COVID-19

> **NCT04421027** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1525 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04421027
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-12
- **Primary completion:** 2021-02-12
- **Final completion:** 2021-06-10
- **Target enrollment:** 1525 (ACTUAL)
- **Last updated:** 2022-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04421027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04421027, "A Study of Baricitinib (LY3009104) in Participants With COVID-19". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04421027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*